<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00391144</url>
  </required_header>
  <id_info>
    <org_study_id>1/2006</org_study_id>
    <nct_id>NCT00391144</nct_id>
  </id_info>
  <brief_title>Avastin for CNV Secondary to Pattern Dystrophy</brief_title>
  <official_title>Intravitreal Avastin Injection for the Treatment of Choroidal Neovascularization Secondary to Pattern Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Trieste</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Trieste</source>
  <brief_summary>
    <textblock>
      The natural history of subfoveal CNV secondary to Pattern Dystrophy is little understood, but
      it seems that visual function may be preserved only in the short-term follow-up, with
      progressive deterioration thereafter.

      Photodynamic therapy with verteporfin is the most studied therapeuthic option for this kindf
      of lesion, but unfortunately, this approach does not appear to guarantee long-term vision
      stabilization, and alternative therapies should be investigated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diagnosis of Pattern Dystrophy Diagnosis of subfoveal CNV Intravitreal injection of avastin
      (1.25 mg) in operating room under sterile condition.

      Retreatment on the basis of the detection of disease progression and of lack of central
      retinal thickness reduction on OCT.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2006</start_date>
  <completion_date>October 2006</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of eyes with &lt;15 letter loss (approximately &lt;3 lines) at 6-month examination compared with the baseline value</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>numeber of eyes with &lt;15 letter loss at 12-month examinations, compared with the baseline value.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>CNV progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of injections.</measure>
  </secondary_outcome>
  <enrollment>5</enrollment>
  <condition>Choroidal Neovascularization Secondary to Pattern Dystrophy</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>intravitreal triamcinolone injection of avastin (1.25 mg)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of RPD (hyperpigmented yellowish-greyish network, other family members
             sharing RPD, normal electroretinogram and normal/subnormal electrooculogram)

          -  classic or occult CNV involving the foveal avascular zoneâ€™s geometric centre

        Exclusion Criteria:

          -  conditions other than RPD

          -  intraocular surgery or capsulotomy within the last 2 or 1 months

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maurizio B Parodi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica Oculistica, Azienda Ospedaliero-Universitaria di Trieste</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierluigi Iacono, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica Oculistica, Azienda Ospedaliero-Universitaria di Trieste</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giuseppe Ravalico, MD</last_name>
    <role>Study Director</role>
    <affiliation>Clinica Oculistica, Azienda Ospedaliero-Universitaria di Trieste</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maurizio B Parodi, MD</last_name>
    <phone>+39 040 772449</phone>
    <email>maubp@yahoo.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Giuseppe Ravalico, MD</last_name>
    <phone>+39 040 772449</phone>
    <email>giuseppe.ravalico@aots.sanita.fvg.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinica Oculistica, Azienda Ospedaliero-Universitaria di Trieste</name>
      <address>
        <city>Trieste</city>
        <state>TS</state>
        <zip>34129</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Ravalico, MD</last_name>
      <phone>+39 040 772449</phone>
      <email>giuseppe.ravalico@aots.sanita.fvg.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Parodi MB, Liberali T, Pedio M, Francis PJ, Piccolino FC, Fiotti N, Romano M, Ravalico G. Photodynamic therapy of subfoveal choroidal neovascularization secondary to reticular pattern dystrophy: three-year results of an uncontrolled, prospective case series. Am J Ophthalmol. 2006 Jun;141(6):1152-4.</citation>
    <PMID>16765697</PMID>
  </results_reference>
  <results_reference>
    <citation>Da Pozzo S, Parodi MB, Toto L, Ravalico G. Occult choroidal neovascularization in adult-onset foveomacular vitelliform dystrophy. Ophthalmologica. 2001 Nov-Dec;215(6):412-4.</citation>
    <PMID>11741106</PMID>
  </results_reference>
  <results_reference>
    <citation>Battaglia Parodi M, Da Pozzo S, Ravalico G. Photodynamic therapy for choroidal neovascularization associated with pattern dystrophy. Retina. 2003 Apr;23(2):171-6.</citation>
    <PMID>12707595</PMID>
  </results_reference>
  <results_reference>
    <citation>Battaglia Parodi M, Di Crecchio L, Ravalico G. Vascularized pigment epithelial detachment in adult-onset foveomacular vitelliform dystrophy. Eur J Ophthalmol. 2000 Jul-Sep;10(3):266-9.</citation>
    <PMID>11071039</PMID>
  </results_reference>
  <results_reference>
    <citation>Battaglia Parodi M, Iustulin D, Russo D, Ravalico G. Adult-onset foveomacular vitelliform dystrophy and indocyanine green videoangiography. Graefes Arch Clin Exp Ophthalmol. 1996 Mar;234(3):208-11.</citation>
    <PMID>8720722</PMID>
  </results_reference>
  <verification_date>October 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2006</study_first_submitted>
  <study_first_submitted_qc>October 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2006</study_first_posted>
  <last_update_submitted>October 20, 2006</last_update_submitted>
  <last_update_submitted_qc>October 20, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2006</last_update_posted>
  <keyword>Pattern Dystrophy</keyword>
  <keyword>Choroidal Neovascularization</keyword>
  <keyword>Intravitreal Avastin Injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>January 26, 2011</submitted>
    <returned>February 22, 2011</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

